logo-loader
viewErgomed PLC

Ergomed's PrimeVigilance supports coronavirus trial

The company is providing the services through its specialist pharmacovigilance provider as part of an ongoing clinical trial

Ergomed PLC -

Ergomed PLC (LON:ERGO) has said it is to provide drug safety services to assess the effect of a rheumatoid arthritis treatment on patients with severe COVID-19 infection caused by coronavirus.

The company is providing the services through its specialist pharmacovigilance provider, PrimeVigilance, as part of an ongoing clinical trial.

"COVID-19 represents a severe and pressing challenge for all involved in the development of new medicines and we are proud to be expanding our involvement in the field by bringing our expertise in drug safety and pharmacovigilance to this programme,” Dr Miroslav Reljanović, the executive chairman of Ergomed said in a statement.

“The rapid initiation of clinical trials and establishment of appropriate safety monitoring will be critical to providing new treatments which may improve outcomes for patients," he added.

Quick facts: Ergomed PLC

Price: 367.5 GBX

AIM:ERGO
Market: AIM
Market Cap: £177.14 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 makes positive start to trading despite further...

Headlines from the Proactive UK newsroom. Oil prices have dropped further after Saudi Arabia and Russia postponed a meeting to discuss production cuts. The two countries started an oil price war last month. Rolls-Royce has built a cash pile of £6.7bn in anticipation of a further...

on 6/4/20

2 min read